Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
- 1 September 2012
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 143 (3) , 608-618.e5
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
- GlaxoSmithKline
- Merck
- Roche
- Bayer
- Bristol-Myers Squibb
- Gilead Sciences
This publication has 13 references indexed in Scilit:
- Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionHepatology, 2012
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C VirusGastroenterology, 2010
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001